Stock Market Reviews

Read and share opinions on MESO (Mesoblast Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Mesoblast Limited (ASX:MSB): Are Analysts Optimistic?
  Nov 12, 2025
• Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
  Nov 10, 2025
• Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
  Nov 4, 2025
• All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
  Oct 29, 2025
• Is Now the Right Moment for Mesoblast After a 82% 12-Month Surge?
  Oct 21, 2025
• Mesoblast (ASX:MSB) SecurES Permanent J-Code for Ryoncil—What Does This Mean for Broader Adoption?
  Oct 20, 2025
• Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
  Oct 19, 2025
• Mesoblast’s Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement
  Oct 16, 2025
• Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
  Oct 6, 2025
• Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge
  Oct 4, 2025
• Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
  Oct 3, 2025
• Mesoblast Limited (MESO)’s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs
  Oct 1, 2025
• Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
  Sep 26, 2025
• Gregory George Bought 40% More Shares In Mesoblast
  Sep 15, 2025
• Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
  Sep 15, 2025
• Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
  Sep 4, 2025